Document:

chke_Ex10_1

		
			Exhibit 10.1
		

		
			FIRST AMENDMENT TO PROMISSORY NOTE
		

		
			THIS FIRST AMENDMENT TO PROMISSORY NOTE, dated as of June 5, 2017 (the “First Amendment”), modifies and amends that certain Promissory Note, dated December 7, 2016 (the “Note”), executed by Irene Acquisition Company B.V., a company organized under the laws of the Netherlands (“Borrower”), payable to the order of Ravich Revocable Trust of 1989 (“Lender”) in the initial principal sum of up to Five Million Dollars ($5,000,000).  The executed original Note is attached hereto.  Terms used and not otherwise defined herein shall have the definitions given such terms in the Note.
		

		
			NOW, THEREFORE,  Borrower and Lender hereby agree as follows:
		

		
			1.         The current principal amount outstanding under the Loan as of the date hereof is One Million Five Hundred Thousand Dollars ($1,500,000). The total amount of accrued and unpaid interest as of the date hereof is Fourteen Thousand Six Hundred Forty-Five Dollars and Eighty-Four Cents ($14,645.84).  The total amount outstanding under the Note as of the date hereof is One Million Five Hundred Fourteen Thousand Six Hundred Forty-Five Dollars and Eighty-Four Cents ($1,514,645.84) (the “June 2017 Outstanding Amount”). 
		

		
			2.         The June 2017 Outstanding Amount shall bear interest at a fixed per annum rate equal to 9.50% from the date hereof,  and to accomplish such change,  Section II.1 of the Note is hereby amended and restated in its entirety as follows:
		

		
			“The principal amount outstanding under the Loan advanced under this Note will bear interest at a fixed per annum rate equal to 9.50%, which interest shall accrue on the Loan commencing on, and including, the date hereof until the outstanding principal amount thereof, together with all accrued and unpaid interest thereon, shall be paid in full in cash in the manner specified in this Note;  provided,  however, any principal amount and any accrued and unpaid interest still outstanding on the Maturity Date (the “June 2017 Outstanding Amount”) shall bear interest at a fixed per annum rate equal to 9.50%, which interest shall accrue on the June 2017 Outstanding Amount commencing on the date after the Maturity Date until the date on which the June 2017 Outstanding Amount, together with all accrued and unpaid interest thereon, has been paid in full in cash in the manner specified in this Note. The June 2017 Outstanding Amount, together with all accrued and unpaid interest thereon, shall be paid in full in cash on or before the New Maturity Date.”
		

		
			3.         The following definitions shall be added to Section VI of the Note in the correct alphabetical order:
		

		
			a.   “June 2017 Outstanding Amount” means One Million Five Hundred Fourteen Thousand Six Hundred Forty-Five Dollars and Eighty-Four Cents ($1,514,645.84).
		

		
			b.   “New Maturity Date” means July 31, 2017.
		

		
			
		

		
			

		 

 

		

		
			4.         As amended hereby, the Note remains in full force and effect and Borrower hereby ratifies, reaffirms and confirms all of the terms and conditions of the Note and all other documents and instruments executed in connection therewith (the “Loan Documents”) in all respects, and hereby acknowledges that the Loan Documents are valid and enforceable obligations against Borrower, due and payable in full, without defenses, setoffs or counterclaims of any kind.  The indebtedness evidenced by the Loan Documents is hereby acknowledged and admitted.
		

		
			 
		

		
			 
		

		
			[signature pages follow]
		

		
			
		

		
			

		 

 

		

		
			IN WITNESS WHEREOF, the parties hereto have executed this First Amendment, and it is effective as of the date first written above.
		

		
			 
		

		
			 
		

			
					
						/

					
					
						 

					
					
						 

				
	
					
						Irene Acquisition Company B.V.,

					
					
						 

				
	
					
						as Borrower

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						By:

					
					
						/s/ Henry Stupp

					
					
						 

				
	
					
						Name:

					
					
						 Henry Stupp

					
					
						 

				
	
					
						Title:

					
					
						 Director A

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						By:

					
					
						/s/ Edward Van Wezel

					
					
						 

				
	
					
						Name:

					
					
						 Edward Van Wezel

					
					
						 

				
	
					
						Title:   

					
					
						 Director B

					
					
						 

				

		
			 
		

		
			
		

		

		 

 

	
					
						

					
						/

					
					
						 

					
					
						 

				
	
					
						Ravich Revocable Trust of 1989,

					
					
						 

				
	
					
						as Lender

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						By:

					
					
						/s/ Jess M. Ravich

					
					
						 

				
	
					
						Name:

					
					
						 Jess M. Ravich

					
					
						 

				
	
					
						Title:

					
					
						 TrusteeBlueprint

 

Exhibit 10(uuu)

 

 

 

 

SECURITIES PURCHASE AGREEMENT

 

 

 

between

 

 

 

CEL-SCI CORPORATION

 

 

 

and

 

 

 

ERGOMED plc

 

 

dated
as of

 

August 15, 2017

 

 

	

 

 

1

 

 

TABLE OF CONTENTS

 

	

ARTICLE I
DEFINITIONS

	

4

	

ARTICLE II
PURCHASE AND SALE

	

6

	

Section 2.01
Purchase and Sale.

	

6

	

Section 2.02
Transactions Effected at the Closing.

	

7

	

Section 2.03
Closing.

	

7

	

ARTICLE III
REPRESENTATIONS AND WARRANTIES OF THE COMPANY

	

7

	

Section 3.01
Organization, Qualification and Authority of the
Company.

	

7

	

Section 3.02 Valid
Issuance of Shares.

	

7

	

Section 3.03 No
Conflicts; Consents.

	

7

	

Section 3.04
Brokers.

	

8

	

Section 3.05
Offering.

	

8

	

Section 3.06
Reports and Financial Statements; Absence of Certain
Changes.

	

8

	

ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF creditor

	

8

	

Section 4.01
Organization and Authority of Creditor.

	

8

	

Section 4.02 No
Conflicts; Consents.

	

9

	

Section 4.03
Restricted Securities.

	

9

	

Section 4.04
Brokers.

	

9

	

ARTICLE V
CONDITIONS TO CLOSING

	

9

	

Section 5.01
Conditions to Obligations of All Parties.

	

9

	

Section 5.02
Conditions to Obligations of Creditor.

	

10

	

Section 5.03
Conditions to Obligations of the Company.

	

11

	

ARTICLE VI
COVENANTS

	

11

	

Section 6.01
Affirmative Covenants of the Company.

	

11

	

Section 6.02
Negative Covenant of Creditor.

	

11

	

Section 6.03
Application of Resale Proceeds.

	

12

	

Section 6.04
Further Assurances.

	

12

 

 

2

 

 

	

ARTICLE VII
INDEMNIFICATION

	

12

	

Section 7.01
Survival.

	

12

	

Section 7.02
Indemnification By Company.

	

12

	

Section 7.03
Payments.

	

12

	

Section 7.04 Tax
Treatment of Indemnification Payments.

	

12

	

Section 7.05
Effect of Investigation.

	

12

	

Section 7.06
Exclusive Remedies.

	

13

	

ARTICLE VIII
MISCELLANEOUS

	

13

	

Section 8.01
Expenses.

	

13

	

Section 8.02
Notices.

	

13

	

Section 8.03
Interpretation.

	

14

	

Section 8.04
Headings.

	

14

	

Section 8.05
Severability.

	

14

	

Section 8.06
Entire Agreement.

	

14

	

Section 8.07
Successors and Assigns.

	

15

	

Section 8.08 No
Third-Party Beneficiaries.

	

15

	

Section 8.09
Amendment and Modification; Waiver.

	

15

	

Section 8.10
Governing Law; Submission to Jurisdiction; Waiver of Jury
Trial.

	

15

	

Section 8.11
Counterparts.

	

16

 

 

3

 

 

SECURITIES PURCHASE AGREEMENT

 

This Securities Purchase Agreement (this
"Agreement"), dated as of August 15, 2017, is entered into
by and between Cel-Sci Corporation, a Colorado corporation (the
"Company") and Ergomed plc, a public limited company
organized under the laws of England and Wales ("Creditor").

Recitals

 

WHEREAS, the Company has authorized the issuance
by the Company of up to 480,000 shares (the "Shares") of the Company’s Common Stock, par value
$0.01 per share (the "Common Stock");

 

WHEREAS, as of the date of this Agreement, the
Company owes Creditor $4,303,203.63, as detailed in
Annex
A (the "Debt"), in connection with a certain co-development
agreement dated as of April 19, 2013, as amended (the
"Co-development
Agreement"), a certain master
services agreement of the same date (the "MSA") and the clinical trial orders making up an
integral part of the MSA (the "CTOs", and together with the Co-development Agreement
and MSA, the "Principal Relationship
Agreements");
and

 

WHEREAS,
the Company wishes to issue the Shares to Creditor in exchange for
Creditor agreeing to provisionally forebear collection of the Debt
and to allow partial satisfaction of the Debt balance in an amount
equal to the Net Proceeds, if any, received by Creditor upon any
resale by Creditor of the Shares, subject to the terms and
conditions set forth herein.

 

NOW,
THEREFORE, in consideration of the mutual covenants and agreements
hereinafter set forth and for other good and valuable
consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto agree as follows:

 

ARTICLE I

DEFINITIONS

 

The
following terms have the meanings specified or referred to in this
Agreement:

 

"Action" means any claim, action, cause of action,
demand, lawsuit, arbitration, inquiry, audit, notice of violation,
proceeding, litigation, citation, summons, subpoena or
investigation of any nature, civil, criminal, administrative,
regulatory or otherwise, whether at law or in
equity.

 

"Affiliate" of a Person means any other Person that directly
or indirectly, through one or more intermediaries, controls, is
controlled by, or is under common control with, such Person. The
term "control" (including the terms "controlled by" and "under
common control with") means the possession, directly or indirectly,
of the power to direct or cause the direction of the management and
policies of a Person, whether through the ownership of voting
securities, by contract or otherwise .

 

"Agreement" has the meaning set forth in the
preamble.

 

"Business Day" means any day except Saturday, Sunday or any
other day on which commercial banks located in London or Colorado
are authorized or required by Law to be closed for
business.

 

 

4

 

 

"Closing" has the meaning set forth in Section 2.03.

 

"Closing Date" has the meaning set forth in Section 2.03.

 

"Co-development
Agreement" has the meaning set
forth in the recitals.

 

"Common Stock" has the meaning set forth in the
recitals.

 

"Company" has the meaning set forth in the
preamble.

 

"Contracts" means all contracts, leases, deeds, mortgages,
licenses, instruments, notes, loans, commitments, undertakings,
indentures, joint ventures and all other agreements, commitments
and legally binding arrangements, whether written or
oral.

 

"Creditor" has the meaning set forth in the
preamble.

 

"Creditor
Indemnitees" has the meaning
set forth in Section
7.02.

 

"CTOs" has the meaning set forth in the
recitals.

 

"Debt" has the meaning set forth in the
recitals.

 

"Disclosure
Schedules" means the Disclosure
Schedules delivered by the Company and Creditor concurrently with
the execution and delivery of this Agreement.

 

"Dollars or $" means the lawful currency of the United
States.

 

"Encumbrance" means any charge, claim, community property
interest, pledge, condition, equitable interest, lien (statutory or
other), option, security interest, mortgage, easement,
encroachment, right of way, right of first refusal, or restriction
of any kind, including any restriction on use, voting, transfer,
receipt of income or exercise of any other attribute of
ownership.

 

"Exchange Act" has the meaning set forth in Section 3.06.

 

"Governmental
Authority" means any federal,
state, local or foreign government or political subdivision
thereof, or any agency or instrumentality of such government or
political subdivision, or any self-regulated organization or other
non-governmental regulatory authority or quasi-governmental
authority (to the extent that the rules, regulations or orders of
such organization or authority have the force of Law), or any
arbitrator, court or tribunal of competent
jurisdiction.

 

"Governmental
Order" means any order, writ,
judgment, injunction, decree, stipulation, determination or award
entered by or with any Governmental Authority.

 

"Law" means any statute, law, ordinance, regulation,
rule, code, order, constitution, treaty, common law, judgment,
decree, other requirement or rule of law of any Governmental
Authority.

 

"Losses" means losses, damages, liabilities,
deficiencies, Actions, judgments, interest, awards, penalties,
fines, costs or expenses of whatever kind, including reasonable
attorneys' fees and the cost of enforcing any right to
indemnification hereunder and the cost of pursuing any insurance
providers; provided, that "Losses" shall not include punitive damages, except in
the case of fraud or to the extent actually awarded to a
Governmental Authority or other third party.

 

 

5

 

 

"Material Adverse
Effect" means any event,
occurrence, fact, condition or change that is, or could reasonably
be expected to become, individually or in the aggregate, materially
adverse to the business, results of operations, prospects,
condition (financial or otherwise) or assets of the
Company.

 

"MSA" has the meaning set forth in the
recitals.

 

"Net Proceeds" means proceeds in cash, checks or wire
transfers, as and when received by Creditor upon the sale of any
Shares, net of out-of-pocket fees, costs and expenses paid or
payable by Creditor as a result of or relating to the sale of the
Shares (including brokers’ fees, commissions or discounts and
other transaction fees incurred in connection with such
sale).

 

"Permits" means all permits, licenses, franchises,
approvals, authorizations, registrations, certificates, variances
and similar rights obtained, or required to be obtained, from
Governmental Authorities.

 

"Person" means an individual, corporation, partnership,
joint venture, limited liability company, Governmental Authority,
unincorporated organization, trust, association or other
entity.

 

"Registration
Statement" has the meaning set
forth in Section
6.01(c).

 

"Representative"
means, with respect to any Person, any and all directors, officers,
employees, consultants, financial advisors, counsel, accountants
and other agents of such Person.

 

"SEC" has the meaning set forth in Section 3.06.

 

"SEC
Documents" has the meaning set
forth in Section
3.06.

 

"Securities
Act" has the meaning set forth
in Section
3.05.

 

"Shares" has the meaning set forth in the
recitals.

 

ARTICLE II

PURCHASE AND SALE

 

Section 2.01 Purchase and Sale.
Subject to the terms and conditions
set forth herein, at the Closing, the Company shall issue 480,000
Shares to Creditor in exchange for Creditor agreeing to
provisionally forbear collection of the Debt and to allow partial
satisfaction of the Debt balance in an amount equal to the Net
Proceeds, if any, from any resales of Shares, subject to
Section 6.01(c) and Section
6.03.

 

Section 2.02 Transactions Effected at the
Closing. 

 

(a) At
the Closing, Creditor shall deliver to the Company:

 

(i) all
documents, instruments or certificates required to be delivered by
Creditor at or prior to the Closing pursuant to Section 5.03 of this Agreement.

 

 

6

 

 

(b) At
the Closing, the Company shall deliver to Creditor:

 

(i) stock
certificates evidencing the Shares; and

 

(ii) all
agreements, documents, instruments or certificates required to be
delivered by the Company at or prior to the Closing pursuant
to Section 5.02
of this Agreement.

 

Section 2.03 Closing. Subject to the terms and conditions of this
Agreement, the purchase and sale of the Shares contemplated hereby
shall take place at a closing (the "Closing") remotely by electronic mail, or at such other
time or on such other date or at such other place or by such other
method as the Company and Creditor may mutually agree upon orally
or in writing (the day on which the Closing takes place, the
"Closing
Date"). If the Closing does not
take place prior to August 28, 2017, either party may terminate
this Agreement by written notice to the other
party.

 

ARTICLE III

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

The Company represents and warrants to Creditor
that the statements contained in this ARTICLE III are true and correct as of the date
hereof.

 

Section 3.01 Organization, Qualification and
Authority of the Company. The
Company is a corporation duly organized, validly existing and in
good standing under the Laws of the state of Colorado and has full
corporate power and authority to (a) enter into this Agreement, to
carry out its obligations hereunder and to consummate the
transactions contemplated hereby. The execution and delivery by the
Company of this Agreement, the performance by the Company of its
obligations hereunder and the consummation by the Company of the
transactions contemplated hereby have been duly authorized by all
requisite corporate action on the part of the Company. This
Agreement has been duly executed and delivered by the Company, and
(assuming due authorization, execution and delivery by Creditor)
this Agreement constitutes a legal, valid and binding obligation of
the Company enforceable against the Company in accordance with its
terms.

 

Section 3.02 Valid Issuance of
Shares. The Shares, when
issued, sold and delivered in accordance with the terms of this
Agreement for the consideration expressed herein, will be duly and
validly issued, fully paid, and non-assessable, and will be free of
any Encumbrances or restrictions on transfer other than
restrictions on transfer under this Agreement or under applicable
securities laws or Encumbrances created or imposed by
Creditor.

 

Section 3.03 No Conflicts; Consents.
The execution, delivery and
performance by the Company of this Agreement, and the consummation
of the transactions contemplated hereby, do not and will not: (a)
conflict with or result in a violation or breach of, or default
under, any provision of the certificate of incorporation, by-laws
or other organizational documents of the Company; (b) conflict with
or result in a violation or breach of any provision of any Law or
Governmental Order applicable to the Company; (c) except as set
forth in Section
3.03 of the Disclosure
Schedules, require the consent or waiver of, notice to or other
action by any Person under, give rise to any rights under, conflict
with, result in a violation or breach of, constitute a default or
an event that, with or without notice or lapse of time or both,
would constitute a default under, result in the acceleration of or
create in any party the right to accelerate, terminate, modify or
cancel any Contract to which the Company is a party or by which the
Company is bound or to which any of its properties and assets are
subject or any Permit affecting the properties, assets or business
of the Company (including without limitation any Contract with
respect to any outstanding rights of first refusal, rights of first
offer, pre-emptive rights, anti-dilution rights ,redemption or
repurchase rights or registration rights); or (d) result in the
creation or imposition of any Encumbrance on any properties or
assets of the Company. Except as set forth in Section 3.03 of the Disclosure Schedules, no consent, approval,
Permit, Governmental Order, declaration or filing with, or notice
to, any Governmental Authority is required by or with respect to
the Company in connection with the execution and delivery of this
Agreement and the consummation of the transactions contemplated
hereby.

 

 

7

 

 

Section 3.04 Brokers. No broker, finder or investment banker is entitled
to any brokerage, finder's or other fee or commission in connection
with the transactions contemplated by this Agreement based upon
arrangements made by or on behalf of the
Company.

 

Section 3.05 Offering. Subject in part to the truth and accuracy of
Creditor’s representations set forth in Article IV of this
Agreement, the offer, sale and issuance of the Shares are exempt
from the registration requirements of the Securities Act of 1933,
as amended (the "Securities
Act"), and will not result in a
violation of the qualification or registration requirements of any
applicable securities laws of any U.S. state or any jurisdiction
outside the U.S., and neither the Company nor any authorized agent
acting on its behalf will take any action hereafter that would
cause the loss of such exemption.

 

Section 3.06  Reports and Financial
Statements; Absence of Certain Changes. The Company has filed all reports, schedules,
forms, statements and other documents required to be filed by the
Company with the Securities and Exchange Commission (the
"SEC") pursuant to the Securities Act and the
reporting requirements of the Securities Exchange Act of 1934, as
amended (the "Exchange Act") (such documents, together with any documents
otherwise filed by the Company with the SEC, the
"SEC
Documents"), and has previously
furnished or made available to Creditor true and complete copies of
such SEC Documents and shall promptly deliver or make available to
Creditor any SEC Documents filed between the date hereof and the
Closing Date. None of such SEC Documents, as of their respective
dates (and as amended through the date hereof), contained or, with
respect to SEC Documents filed after the date hereof, will contain
any untrue statement of material fact or omit to state a material
fact required to be stated therein or necessary to make the
statements therein, in light of the circumstances under which they
were made, not misleading. Since June 30, 2017, there has been no
event that would have a Material Adverse Effect, except as
disclosed in Section
3.06 of the Disclosure
Schedules and in the SEC Documents.

 

ARTICLE IV

REPRESENTATIONS AND WARRANTIES OF CREDITOR

 

Creditor represents and warrants to the Company
that the statements contained in this ARTICLE IV are true and correct as of the date
hereof.

 

Section 4.01 Organization and Authority of
Creditor. Creditor is a public
limited company properly organized under the Laws of England and
Wales. Creditor has all requisite power and authority to enter into
this Agreement, to carry out its obligations hereunder and to
consummate the transactions contemplated hereby. The execution and
delivery by Creditor of this Agreement, the performance by Creditor
of its obligations hereunder and the consummation by Creditor of
the transactions contemplated hereby have been duly authorized by
all requisite action on the part of Creditor. This Agreement has
been duly executed and delivered by Creditor, and (assuming due
authorization, execution and delivery by the Company) this
Agreement constitutes a legal, valid and binding obligation of
Creditor enforceable against Creditor in accordance with its
terms.

 

 

8

 

 

Section 4.02 No Conflicts; Consents.
The execution, delivery and
performance by Creditor of this Agreement, and the consummation of
the transactions contemplated hereby, do not and will not: (a)
conflict with or result in a violation or breach of, or default
under, any provision of the constitutional or other organizational
documents of Creditor; (b) conflict with or result in a violation
or breach of any provision of any Law or Governmental Order
applicable to Creditor; or (c) require the consent, notice or other
action by any Person under any Contract to which Creditor is a
party. No consent, approval, Permit, Governmental Order,
declaration or filing with, or notice to, any Governmental
Authority is required by or with respect to Creditor in connection
with the execution and delivery of this Agreement and the
consummation of the transactions contemplated
hereby.

 

Section 4.03 Restricted Securities.
Creditor acknowledges that the Shares
are not registered under the Securities Act, or any state
securities laws, and that the Shares may not be transferred or sold
except pursuant to the registration provisions of the Securities
Act or pursuant to an applicable exemption therefrom and subject to
state securities laws and regulations, as
applicable.

 

Section 4.04 Brokers. No broker, finder or investment banker is entitled
to any brokerage, finder's or other fee or commission in connection
with the transactions contemplated by this Agreement based upon
arrangements made by or on behalf of Creditor.

 

ARTICLE
V  

CONDITIONS TO CLOSING

 

Section 5.01 Conditions to Obligations of
All Parties. The obligations of
each party to consummate the transactions contemplated by this
Agreement shall be subject to the fulfilment, at or prior to the
Closing, of each of the following conditions:

 

(a) No
Governmental Authority shall have enacted, issued, promulgated,
enforced or entered any Governmental Order which is in effect and
has the effect of making the transactions contemplated by this
Agreement illegal, otherwise restraining or prohibiting
consummation of such transactions or causing any of the
transactions contemplated hereunder to be rescinded following
completion thereof.

 

(b) The
Company shall have received all consents, authorizations, orders
and approvals from the Governmental Authorities referred to
in Section 3.03, in each
case, in form and substance reasonably satisfactory to Creditor and
the Company, and no such consent, authorization, order and approval
shall have been revoked.

 

 

9

 

 

Section 5.02 Conditions to Obligations of
Creditor. The obligations of
Creditor to consummate the transactions contemplated by this
Agreement shall be subject to the fulfillment or Creditor's waiver
(with the exception of (b) below), at or prior to the Closing, of
each of the following conditions:

 

(a) The
representations and warranties of the Company contained in Article
III shall be true on and as of the Closing with the same effect as
though such representations and warranties had been made on and as
of the Closing Date.

 

(b)  The
Company will have received the approval of the NYSE American for
the issuance of the Shares. The Company (i) will take all
reasonable steps to obtain such approval as soon as possible, (ii)
maintain the listing until all of the Shares have been sold or
returned to the Company and (iii) pay all of the reasonable and
customary fees and expenses incurred in connection with the listing
of the Shares. In the event that the Shares are not listed with the
NYSE American in accordance with the foregoing or the listing
ceases to be maintained at any time, Creditor shall have a right to
return any unsold Shares to the Company for
cancellation.

 

(c) This
Agreement shall have been executed and delivered by the parties
thereto and true and complete copies thereof shall have been
delivered to Creditor.

 

(d) Creditor
shall have received a certificate of the Secretary or an Assistant
Secretary (or equivalent officer) of the Company
certifying:

 

(i) that
attached thereto are true and complete copies of all resolutions
and other consents adopted by the board of directors and
stockholders of the Company authorizing and approving the
execution, delivery, filing and performance of this Agreement and
the consummation of the transactions contemplated hereby, and that
all such resolutions and consents are in full force and effect as
of the Closing and are all the resolutions and consents adopted in
connection with the transactions contemplated hereby;

 

(ii) that
attached thereto are true and complete copies of the certificate of
incorporation and by-laws of the Company and that such
organizational documents are in full force and effect as of the
Closing; and

 

(iii) the
names and signatures of the officers of the Company authorized to
sign this Agreement and the other documents to be delivered
hereunder.

 

(e) The
Company shall have delivered to Creditor a good standing
certificate (or its equivalent) for the Company from the secretary
of state or similar Governmental Authority of the jurisdiction
under the Laws in which the Company is organized.

 

(f) The
Company shall have delivered, or caused to be delivered, to
Creditor each of the following, each in form and substance
satisfactory to Creditor:

 

(i) stock
certificates evidencing the Shares; and

 

(ii) such
other documents or instruments as Creditor reasonably requests and
are reasonably necessary to consummate the transactions
contemplated by this Agreement.

 

 

10

 

 

Section 5.03 Conditions to Obligations of
the Company. The obligations of
the Company to consummate the transactions contemplated by this
Agreement shall be subject to the fulfillment or the Company's
waiver, at or prior to the Closing, of each of the following
conditions:

 

(a) The
representations and warranties of Creditor contained in Article IV
shall be true on and as of the Closing with the same effect as
though such representations and warranties had been made on and as
of the Closing Date.

 

(b) This
Agreement shall have been executed and delivered by the parties
thereto and true and complete copies thereof shall have been
delivered to the Company.

 

ARTICLE VI

COVENANTS

 

Section 6.01 Affirmative Covenants of the
Company. Unless the Company has
received the prior written consent or waiver of Creditor, the
Company shall be subject to each of the following
covenants:

 

(a) The
Company shall at all times maintain under the Laws of the state of
Colorado its valid corporate existence and good standing and (ii)
all material Permits necessary to the conduct of its
businesses.

 

(b) The
Company shall comply with all Laws applicable to it or its
business, properties or assets, the violation of which would
reasonably be expected to have a Material Adverse
Effect.

 

(c) Promptly following the Closing, the Company shall
register the Shares under a Registration Statement on Form S-1
under the Securities Act (the "Registration
Statement"). The Company (i)
will take all reasonable steps to have the Registration Statement
declared effective as soon as possible, (ii) maintain the
effectiveness of such Registration Statement until all of the
Shares have been sold thereunder or the Shares can be sold pursuant
to Rule 144 of the Securities Act, and (iii) pay all of the
reasonable and customary fees and expenses incurred in connection
with the registration of the Shares. In the event that the Shares
are not registered on the Registration Statement in accordance with
the preceding sentence or the Registration Statement ceases to be
effective at any time, Creditor shall have a right to return any
unsold Shares to the Company for cancellation.

 

 

 

(d) In
the event that for any reason any of the Shares have not been
resold by Creditor as of December 31, 2017, Creditor may, as its
option, return the Shares to the Company for
cancellation.

 

(e) The
Company shall perform and observe all of its obligations and
covenants set forth in this Agreement.

 

Section 6.02  Negative Covenant of
Creditor. Unless Creditor has
received the prior written consent or waiver of the Company,
Creditor shall not sell more than 5% of that day’s trading
volume on any single day.

 

 

11

 

 

Section 6.03 Application of Resale
Proceeds. Creditor hereby
agrees that the Net Proceeds, if any, received by Creditor upon any
resale by Creditor of the Shares, up to an aggregate of
$4,303,203.63, shall be applied towards satisfaction of the Debt
and any Net Proceeds received in excess of such amount shall be
applied towards satisfaction of any future amounts owed to Creditor
by the Company in connection with the Principal Relationship
Agreements.

 

Section 6.04 Further Assurances.
Following the Closing, each of the
parties hereto shall, and shall cause their respective Affiliates
to, execute and deliver such additional documents, instruments,
conveyances and assurances and take such further actions as may be
reasonably required to carry out the provisions hereof and give
effect to the transactions contemplated by this
Agreement.

 

 ARTICLE
VII

INDEMNIFICATION

 

Section 7.01 Survival. The representations and warranties,
covenants and agreements contained herein shall survive the Closing
and shall remain in full force and effect following the Closing
Date.

 

Section 7.02 Indemnification By
Company. Subject to the other
terms and conditions of this ARTICLE VII, the Company shall indemnify and
defend each of Creditor and its Affiliates and their respective
Representatives (collectively, the "Creditor
Indemnitees") against, and
shall hold each of them harmless from and against, and shall pay
and reimburse each of them for, any and all Losses incurred or
sustained by, or imposed upon, the Creditor Indemnitees based upon,
arising out of, with respect to or by reason
of:

 

(a) any
inaccuracy in or breach of any of the representations or warranties
of the Company contained in this Agreement or in any certificate or
instrument delivered by or on behalf of the Company pursuant to
this Agreement; or

 

(b) any
breach or non-fulfillment of any covenant, agreement or obligation
to be performed by the Company pursuant to this
Agreement.

 

Section 7.03 Payments. Once a Loss is agreed to by the Company or finally
adjudicated to be payable pursuant to this ARTICLE VII, the Company shall satisfy its
obligations within 15 Business Days of such agreement or final,
non-appealable adjudication by wire transfer of immediately
available funds.

 

Section 7.04 Tax Treatment of
Indemnification Payments. All
indemnification payments made under this Agreement shall be treated
by the parties as an adjustment to the Net Proceeds for Tax
purposes, unless otherwise required by Law.

 

Section 7.05 Effect of Investigation.
Neither the representations,
warranties and covenants of the Company, nor the right to
indemnification of any Creditor Indemnitee making a claim under
this ARTICLE VII
with respect thereto, shall be
affected or deemed waived by reason of any investigation made by or
on behalf of an Creditor Indemnitee (including by any of its
Representatives) or by reason of the fact that an Creditor
Indemnitee or any of its Representatives knew or should have known
that any such representation or warranty is, was or might be
inaccurate or by reason of an Creditor Indemnitee's waiver of any
condition set forth in Section 5.02.

 

12

 

 

Section 7.06 Exclusive Remedies.
The parties acknowledge and agree that
their sole and exclusive remedy with respect to any and all claims
(other than claims arising from breach of contract, fraud, criminal
activity or willful misconduct on the part of a party hereto in
connection with the transactions contemplated by this Agreement)
for any breach of any representation, warranty, covenant, agreement
or obligation set forth herein or otherwise relating to the subject
matter of this Agreement, shall be pursuant to the indemnification
provisions set forth in this ARTICLE VII. In furtherance of the
foregoing, each party hereby waives, to the fullest extent
permitted under Law, any and all rights, claims and causes of
action for any breach of any representation, warranty, covenant,
agreement or obligation set forth herein or otherwise relating to
the subject matter of this Agreement it may have against the other
parties hereto and their Affiliates and each of their respective
Representatives arising under or based upon any Law, except
pursuant to the indemnification provisions set forth in this
ARTICLE VII. Nothing in
this Section 7.06
shall limit any Person's right to seek
and obtain any equitable relief to which any Person shall be
entitled or to seek any remedy on account of any party's
fraudulent, criminal or intentional misconduct.

 

 ARTICLE
VIII

MISCELLANEOUS

 

Section 8.01 Expenses. Except as otherwise expressly provided herein, all
costs and expenses of either party, including, without limitation,
fees and disbursements of counsel, financial advisors and
accountants, incurred in connection with this Agreement and the
transactions contemplated hereby shall be paid by the party who
incurred the costs and expenses.

 

Section 8.02 Notices. All notices, requests, consents, claims, demands,
waivers and other communications hereunder shall be in writing and
shall be deemed to have been given (a) when delivered by hand (with
written confirmation of receipt); (b) when received by the
addressee if sent by a nationally recognized overnight courier
(receipt requested); (c) on the date sent by facsimile or e-mail of
a PDF document (with confirmation of transmission) if sent during
normal business hours of the recipient, and on the next Business
Day if sent after normal business hours of the recipient or (d) on
the seventh day after the date mailed, by certified or registered
mail, return receipt requested, postage prepaid. Such
communications must be sent to the respective parties at the
following addresses (or at such other address for a party as shall
be specified in a notice given in accordance with this
Section
8.02):

 

If to the Company: 

CEL-SCI
Corporation

8229
Boone Boulevard, Suite 802

Vienna,
Virginia 22182

Facsimile:
(703) 506-9471

E-mail: grkersten@cel-sci.com,

Attention:
Geert
Kersten, Chief Executive Officer

 

with a copy to: 

Hart
& Hart, LLC

Facsimile: (303) 839-5414

E-mail: harttrinen@aol.com

Attention: William T. Hart

 

If to Creditor: 

Ergomed
plc

The
Surrey Research Park

26-28
Frederick Sanger Road

Guildford, Surrey
GU2 7YD

United
Kingdom

Facsimile:
+385 1 4628 501

E-mail: stephen.stamp@ergomedplc.com

Attention:
Stephen Stamp, Chief Financial Officer

 

13

 

 

 

with a copy to: 

Covington
& Burling LLP

265
Strand

London
WC2R 1BH

Facsimile: +44 20 7067 2222

E-mail: kwiggert@cov.com

Attention: Kristian Wiggert

 

Section 8.03 Interpretation.
For purposes of this Agreement, (a)
the words "include," "includes" and "including" shall be deemed to
be followed by the words "without limitation"; (b) the word "or" is
not exclusive; and (c) the words "herein," "hereof," "hereby,"
"hereto" and "hereunder" refer to this Agreement as a whole. Unless
the context otherwise requires, references herein: (x) to Articles,
Sections, Disclosure Schedules and Exhibits mean the Articles and
Sections of, and Disclosure Schedules and Exhibits attached to,
this Agreement; (y) to an agreement, instrument or other document
means such agreement, instrument or other document as amended,
supplemented and modified from time to time to the extent permitted
by the provisions thereof and (z) to a statute means such statute
as amended from time to time and includes any successor legislation
thereto and any regulations promulgated thereunder. This Agreement
shall be construed without regard to any presumption or rule
requiring construction or interpretation against the party drafting
an instrument or causing any instrument to be drafted. The
Disclosure Schedules and Exhibits referred to herein shall be
construed with, and as an integral part of, this Agreement to the
same extent as if they were set forth verbatim
herein.

 

Section 8.04 Headings. The headings in this Agreement are for reference
only and shall not affect the interpretation of this
Agreement.

 

Section 8.05 Severability.
If any term or provision of this
Agreement is invalid, illegal or unenforceable in any jurisdiction,
such invalidity, illegality or unenforceability shall not affect
any other term or provision of this Agreement or invalidate or
render unenforceable such term or provision in any other
jurisdiction. Upon such determination that any term or other
provision is invalid, illegal or unenforceable, the parties hereto
shall negotiate in good faith to modify this Agreement so as to
effect the original intent of the parties as closely as possible in
a mutually acceptable manner in order that the transactions
contemplated hereby be consummated as originally contemplated to
the greatest extent possible.

 

Section 8.06 Entire Agreement.
This Agreement constitutes the sole
and entire agreement of the parties to this Agreement with respect
to the subject matter contained herein and therein, and supersedes
all prior and contemporaneous understandings and agreements, both
written and oral, with respect to such subject matter. In the event
of any inconsistency between the statements in the body of this
Agreement and those in the Exhibits and Disclosure Schedules (other
than an exception expressly set forth as such in the Disclosure
Schedules), the statements in the body of this Agreement will
control.

 

 

14

 

 

Section 8.07 Successors and Assigns.
This Agreement shall be binding upon
and shall inure to the benefit of the parties hereto and their
respective successors and permitted assigns. Neither party may
assign its rights or obligations hereunder without the prior
written consent of the other party, which consent shall not be
unreasonably withheld or delayed; provided, that Creditor may,
without the prior written consent of the Company, assign all or any
portion of its rights under this Agreement to one or more of its
direct or indirect wholly-owned subsidiaries. No assignment shall
relieve the assigning party of any of its obligations
hereunder.

 

Section 8.08 No Third-Party
Beneficiaries. Except as
provided in ARTICLE VII,
this Agreement is for the sole benefit of the parties hereto and
their respective successors and permitted assigns and nothing
herein, express or implied, is intended to or shall confer upon any
other Person or entity any legal or equitable right, benefit or
remedy of any nature whatsoever under or by reason of this
Agreement.

 

Section 8.09 Amendment and Modification;
Waiver. This Agreement may only
be amended, modified or supplemented by an agreement in writing
signed by each party hereto. No waiver by any party of any of the
provisions hereof shall be effective unless explicitly set forth in
writing and signed by the party so waiving. No waiver by any party
shall operate or be construed as a waiver in respect of any
failure, breach or default not expressly identified by such written
waiver, whether of a similar or different character, and whether
occurring before or after that waiver. No failure to exercise, or
delay in exercising, any right, remedy, power or privilege arising
from this Agreement shall operate or be construed as a waiver
thereof; nor shall any single or partial exercise of any right,
remedy, power or privilege hereunder preclude any other or further
exercise thereof or the exercise of any other right, remedy, power
or privilege.

 

Section 8.10 Governing Law; Submission to
Jurisdiction; Waiver of Jury Trial. 

 

(a) This
Agreement shall be governed by and construed in accordance with the
internal laws of the State of New York without giving effect to any
choice or conflict of law provision or rule (whether of the State
of New York or any other jurisdiction).

 

(b) ANY
LEGAL SUIT, ACTION OR PROCEEDING ARISING OUT OF OR BASED UPON THIS
AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY MAY BE INSTITUTED
IN THE FEDERAL COURTS OF THE UNITED STATES OF AMERICA OR THE COURTS
OF THE STATE OF NEW YORK IN EACH CASE LOCATED IN THE CITY OF NEW
YORK AND COUNTY OF NEW YORK, AND EACH PARTY IRREVOCABLY SUBMITS TO
THE EXCLUSIVE JURISDICTION OF SUCH COURTS IN ANY SUCH SUIT, ACTION
OR PROCEEDING. SERVICE OF PROCESS, SUMMONS, NOTICE OR OTHER
DOCUMENT BY MAIL TO SUCH PARTY'S ADDRESS SET FORTH HEREIN SHALL BE
EFFECTIVE SERVICE OF PROCESS FOR ANY SUIT, ACTION OR OTHER
PROCEEDING BROUGHT IN ANY SUCH COURT. THE PARTIES IRREVOCABLY AND
UNCONDITIONALLY WAIVE ANY OBJECTION TO THE LAYING OF VENUE OF ANY
SUIT, ACTION OR ANY PROCEEDING IN SUCH COURTS AND IRREVOCABLY WAIVE
AND AGREE NOT TO PLEAD OR CLAIM IN ANY SUCH COURT THAT ANY SUCH
SUIT, ACTION OR PROCEEDING BROUGHT IN ANY SUCH COURT HAS BEEN
BROUGHT IN AN INCONVENIENT FORUM.

 

 

15

 

 

(c) EACH
PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE
UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT
ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY AND
UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN
RESPECT OF ANY LEGAL ACTION ARISING OUT OF OR RELATING TO THIS
AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY TO
THIS AGREEMENT CERTIFIES AND ACKNOWLEDGES THAT (A) NO
REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR
OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE THE
FOREGOING WAIVER IN THE EVENT OF A LEGAL ACTION, (B) SUCH PARTY HAS
CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C) SUCH PARTY MAKES
THIS WAIVER VOLUNTARILY, AND (D) SUCH PARTY HAS BEEN INDUCED TO
ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL
WAIVERS AND CERTIFICATIONS IN THIS SECTION 10.10(c).

 

Section 8.11 Counterparts.
This Agreement may be executed in
counterparts, each of which shall be deemed an original, but all of
which together shall be deemed to be one and the same agreement. A
signed copy of this Agreement delivered by facsimile, e-mail or
other means of electronic transmission shall be deemed to have the
same legal effect as delivery of an original signed copy of this
Agreement.

 

 

 

[SIGNATURE
PAGE FOLLOWS]

 

16

 

 

            

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to
be executed as of the date first written above by their respective
officers thereunto duly authorized.

 

CEL-SCI CORPORATION

 

By: /s/ Geert R.
Kersten 

Name:
Geert R. Kersten

Title:
Chief Executive Officer

 

ERGOMED plc

 

By: /s/ Stephen
Stamp

Name:
Stephen Stamp

Title:
Chief Financial Officer

 

 

 

 

 

17

 

ANNEX A

 

See
Attached.

 

 

 

 

 

 

 

 

 

A-1

 

 

 

	
 

	
 

	

Invoice #

	
 

	

 Invoice Amount

	
 

	

Payment(s) received

	
 

	

Net

	
 

	

Cumulative Debt

	
 

	
 

	
 

	
 

	

 $

	
 

	

 $

	
 

	

 $

	
 

	

 $

	

Aug-16

	
 

	

459/16

	
 

	

     141,620.50

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

460/16

	
 

	

     181,839.36

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

461/16

	
 

	

          7,250.34

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

462/16

	
 

	

        37,331.87

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

463/16

	
 

	

        24,128.15

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

464/16

	
 

	

          3,357.40

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

484/16

	
 

	

        50,960.00

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

     446,487.62

	
 

	

  399,874.33

	
 

	

        46,613.29

	
 

	

           46,613.29

	

Sep-16

	
 

	

531/16

	
 

	

     196,508.08

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

532/16

	
 

	

        31,972.50

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

533/16

	
 

	

        30,412.53

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

534/16

	
 

	

          4,667.76

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

535/16

	
 

	

        46,256.49

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

536/16

	
 

	

        44,010.50

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

537/16

	
 

	

     141,620.50

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

     495,448.36

	
 

	

  271,130.54

	
 

	

     224,317.82

	
 

	

        270,931.11

	

Oct-16

	
 

	

570/16

	
 

	

     188,836.39

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

571/16

	
 

	

          5,750.95

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

572/16

	
 

	

     109,509.46

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

573/16

	
 

	

        55,373.26

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

574/16

	
 

	

     141,620.50

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

575/16

	
 

	

        42,577.92

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

576/16

	
 

	

        25,970.00

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

     569,638.48

	
 

	

  190,000.00

	
 

	

     379,638.48

	
 

	

        650,569.59

	

Nov-16

	
 

	

634/16

	
 

	

     141,620.50

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

635/16

	
 

	

     143,676.44

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

636/16

	
 

	

          1,917.70

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

637/16

	
 

	

        20,026.75

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

638/16

	
 

	

        39,312.23

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

645/16

	
 

	

        21,192.50

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

650/16

	
 

	

             407.48

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

     368,153.60

	
 

	

    78,859.17

	
 

	

     289,294.43

	
 

	

        939,864.02

	

Dec-16

	
 

	

722/16

	
 

	

     141,620.50

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

723/16

	
 

	

     155,478.54

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

724/16

	
 

	

          5,003.27

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

725/16

	
 

	

        23,152.50

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

726/16

	
 

	

        25,469.50

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

727/16

	
 

	

        28,350.23

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

728/16

	
 

	

          5,648.28

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

764/16

	
 

	

     122,422.97

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

767/16

	
 

	

             318.33

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

     507,464.12

	
 

	

  253,732.06

	
 

	

     253,732.06

	
 

	

     1,193,596.08

 

 

A-2

 

 

 

	

 

	
 

	

 
Invoice
#

	
 

	

 Invoice Amount 

	
 

	
Payment(s)
received

	
 

	
Net

	
 

	
Cumulative
Debt

	

Jan-17

	
 

	

041/17

	
 

	

          1,268.54

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

040/17

	
 

	

        24,387.73

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

012/17

	
 

	

     967,764.00

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

042/17

	
 

	

     141,620.50

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

038/17

	
 

	

        69,955.47

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

039/17

	
 

	

          4,338.48

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

013/17

	
 

	

     315,020.33

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

050/17

	
 

	

     535,980.70

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

051/17

	
 

	

        98,785.94

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

052/17

	
 

	

     120,630.91

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

053/17

	
 

	

          5,405.40

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

054/17

	
 

	

          5,292.00

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

055/17

	
 

	

        46,862.23

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

CN
002/17 / 040/17

	
 

	

-
454.50

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

  2,336,857.73

	
 

	

  250,000.00

	
 

	

  2,086,857.73

	
 

	

     3,280,453.81

	

Feb-17

	
 

	

104/17

	
 

	

        19,010.17

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

105/17

	
 

	

          1,776.48

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

106/17

	
 

	

        39,028.26

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

107/17

	
 

	

        18,705.03

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

108/17

	
 

	

     141,620.50

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

109/17

	
 

	

          3,820.45

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

122/17

	
 

	

        29,890.00

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

     253,850.89

	
 

	

  250,000.00

	
 

	

          3,850.89

	
 

	

     3,284,304.70

	

Mar-17

	
 

	

162/17

	
 

	

        25,320.43

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

163/17

	
 

	

        22,468.24

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

161/17

	
 

	

          1,776.48

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

164/17

	
 

	

     141,620.50

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

166/17

	
 

	

          4,606.29

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

165/17

	
 

	

        15,312.50

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

160/17

	
 

	

        59,599.48

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

     270,703.92

	
 

	

  250,000.00

	
 

	

        20,703.92

	
 

	

     3,305,008.62

	

Apr-17

	
 

	

206/17

	
 

	

        59,522.35

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

207/17

	
 

	

          4,135.48

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

208/17

	
 

	

        94,255.29

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

209/17

	
 

	

17,627.62

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

210/17

	
 

	

     141,620.50

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

211/17

	
 

	

          8,207.50

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

223/17

	
 

	

        39,322.50

	
 

	
 

	
 

	
 

	
 

	
 

	

PAW

	
 

	

212/17

	
 

	

        11,022.88

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

     375,714.13

	
 

	

  250,000.00

	
 

	

     125,714.13

	
 

	

     3,430,722.75

	

May-17

	
 

	

256/17

	
 

	

        33,583.82

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

257/17

	
 

	

          2,612.06

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

258/17

	
 

	

        41,926.16

	
 

	
 

	
 

	
 

	
 

	
 

 

 

A-3

 

 

 

	
 

	
 

	

 
Invoice
#

	
 

	

 Invoice Amount 

	
 

	
Payment(s)
received

	
 

	
Net

	
 

	
Cumulative
Debt

	
 

	
 

	

259/17

	
 

	

        11,250.17

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

260/17

	
 

	

     141,620.50

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

261/17

	
 

	

        29,032.50

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

280/17

	
 

	

        13,230.00

	
 

	
 

	
 

	
 

	
 

	
 

	

PAW

	
 

	

262/17

	
 

	

          1,446.89

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

     274,702.09

	
 

	

                    -

	
 

	

     274,702.09

	
 

	

     3,705,424.84

	

Jun-17

	
 

	

302/17

	
 

	

        41,239.53

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

303/17

	
 

	

          4,641.10

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

304/17

	
 

	

     230,689.18

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

305/17

	
 

	

        18,325.40

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

306/17

	
 

	

          6,492.50

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

307/17

	
 

	

     141,620.50

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

329/17

	
 

	

          2,205.00

	
 

	
 

	
 

	
 

	
 

	
 

	

PAW

	
 

	

333/17

	
 

	

             484.70

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

     445,697.91

	
 

	

                    -

	
 

	

     445,697.91

	
 

	

     4,151,122.75

	

Jul-17

	
 

	

CN047/17

	
 

	

-
96,456.50

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

383/17

	
 

	

        21,971.58

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

384/17

	
 

	

          2,594.35

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

049/17

	
 

	

-
70,133.39

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

385/17

	
 

	

        18,754.77

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

386/17

	
 

	

        58,923.35

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

387/17

	
 

	

     209,296.69

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

388/17

	
 

	

          6,725.25

	
 

	
 

	
 

	
 

	
 

	
 

	

PAW

	
 

	

396/17

	
 

	

              404.78

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

     152,080.88

	
 

	

                    -

	
 

	

     152,080.88

	
 

	

     4,303,203.63

 

 

 

A-4

 

 

DISCLOSURE SCHEDULES

 

Section 3.03 Approval of the issuance of the Shares by the
NYSE American.

 

 

 

EXHIBITS

 

None.

 

 

 

 

 

 

A-5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00274-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00274-of-00352.parquet"}]]